GENFIT Overview
Pro stress-test →GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. In 2024, GENFIT achieved accelerated approval of Iqirvo® (elafibranor) by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of Primary Biliary Cholangitis (PBC). Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH).
Strategic Profile
Pro stress-test →GENFIT focuses on Acute on-chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE), developing therapeutic assets with complementary mechanisms of action, and also targets other serious diseases such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital.
Competitive Landscape
Pro stress-test →GENFIT addresses the rare liver disease market with unmet medical needs. The company competes in specialized sectors: Primary Biliary Cholangitis (through approved Iqirvo®), ACLF treatment candidates, and liver disease diagnostics. Key competitive advantage stems from its long heritage in liver disease research and recent regulatory approval of its lead asset.
Industry Context
GENFIT operates in Specialty Biopharmaceuticals (Rare Liver Diseases).
Key facts
Founded: 1999 · Headquarters: Lille, France · Revenue: €65.4 million